Sofosbuvir: an all-around drug in hepatitis C treatment new era – The first phase

Reviews in Health Care

View Publication Info
 
 
Field Value
 
Title Sofosbuvir: an all-around drug in hepatitis C treatment new era – The first phase
 
Creator Ciancio, Alessia
 
Subject
Chronic hepatitis C virus; Sofosbuvir; Protease inhibitor
 
Description Chronic hepatitis C virus (HCV) infection is a slowly progressive disease affecting more than 185 million people worldwide. For many years, the combination of pegylated interferon (Peg-IFN) plus ribavirin (RBV) has been the backbone of treatment for patients infected with HCV. More than two years ago, the first generation direct-acting antiviral agents (DAAs) – the protease inhibitors boceprevir and telaprevir – were approved for treatment of genotype 1 patients, doubling the cure rate. The new DAAs that have been developed, are effective for multiple genotypes, improve rates of sustained viral response with fewer side effects, simplify dosing and drug-drug interactions, and in some patients, offer the promise of interferon-free and/or ribavirin-free therapy. These new agents include the recently approved second generation protease inhibitor, the HCV NS5B polymerase inhibitor sofosbuvir and the NS3/4A protease inhibitor simeprevir as well as several other agents that are currently in later phases of development. With sofosbuvir-based regimens, successful interferon-free treatment is now available across all genotypes. In fact sofosbuvir is very effective in combination with Peg-interferon and ribavirine or with ribavirine alone or with other direct anti-viral agents. The following assessment evaluates the evidence on the clinical effectiveness and harms of sofosbuvir for the treatment of chronic hepatitis C.
 
Publisher SEEd
 
Contributor
 
Date 2015-04-30
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion


 
Format text/html
application/pdf
 
Identifier https://journals.edizioniseed.it/index.php/rhc/article/view/1164
10.7175/rhc.v6i2.1164
 
Source Reviews in Health Care; Vol 6, No 2 (2015); 41-52
2038-6702
2038-6699
 
Language eng
 
Relation https://journals.edizioniseed.it/index.php/rhc/article/view/1164/1397
https://journals.edizioniseed.it/index.php/rhc/article/view/1164/1398
 
Coverage


 
Rights Copyright (c) 2015 Seed
http://creativecommons.org/licenses/by-nc/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library